losartan has been researched along with dipyridamole in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (11.11) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 4 (44.44) | 24.3611 |
2020's | 2 (22.22) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Frohlich, ED; Hosoya, K; Nunez, E; Susic, D | 1 |
Tang, X | 1 |
Gejyo, F; Hiura, T; Kawabe, S; Miyamura, S; Nishi, S; Saeki, T; Ueno, M; Yamazaki, H | 1 |
3 review(s) available for losartan and dipyridamole
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
Nephrotic syndrome and IgA nephropathy in polycystic kidney disease.
Topics: Aged; Biopsy; Dipyridamole; Glomerulonephritis, IGA; Humans; Kidney; Losartan; Male; Nephrotic Syndrome; Polycystic Kidney, Autosomal Dominant; Prednisolone; Thiazepines | 2006 |
1 trial(s) available for losartan and dipyridamole
Article | Year |
---|---|
[Effect of ligustrazine on proliferative glomerulonephritis].
Topics: Adolescent; Adult; Creatinine; Cyclophosphamide; Dipyridamole; Drug Therapy, Combination; Female; Fibrinolytic Agents; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Humans; Losartan; Male; Middle Aged; Prednisone; Pyrazines; Serum Albumin | 2003 |
5 other study(ies) available for losartan and dipyridamole
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Coronary Circulation; Dipyridamole; Enalapril; Heart; Hemodynamics; Hypertrophy, Left Ventricular; Imidazoles; Losartan; Male; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Vasodilator Agents | 1997 |